Enanta Pharmaceuticals | ENTA - Debt


Enanta Pharmaceuticals reported $1.35M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Amgen USD 54.59B 1.62B Sep/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.29B 1.7M Dec/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Incyte USD 40.41M 855K Dec/2025
Insmed USD 727.89M 163.33M Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
J&J USD 45.8B 4.97B Sep/2025
Karyopharm Therapeutics USD 264.09M 39.31M Sep/2024
Ligand Pharmaceuticals USD 451M 445.26M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025